Eribulin alone

Phase 3Small molecule

Eisai

Eribulin alone is one of 101 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Eribulin alone

Eisai

Phase 3

2 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Prolia

Amgen

Preclinical

14 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recruiting·SShanghai Yizhong Pharmaceutical Co., Ltd.·Phase 3·NCT06143553·168 enrolled

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Terminated·SSwiss Cancer Institute·Phase 2·NCT02404506·78 enrolled

Refractory or Recurrent Solid Tumor1 trial

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Completed· Eisai logo

Eisai·Phase 1/2·NCT03245450·40 enrolled

Non-Small Cell Lung Cancer1 trial

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Completed· Eisai logo

Eisai·Phase 2·NCT01104155·123 enrolled

Soft Tissue Sarcoma1 trial

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Completed· Eisai logo

Eisai·Phase 3·NCT01327885·452 enrolled

Patients With Advanced Solid Tumors1 trial

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Completed· Eisai logo

Eisai·Phase 1·NCT01000376·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Eribulin alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eribulin alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eribulin alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eisai

Eribulin alone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Refractory or Recurrent Solid Tumor1 trial

Non-Small Cell Lung Cancer1 trial

Soft Tissue Sarcoma1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News